Bristol Myers rises, AbbVie sinks

AbbVie tumbles after new schizophrenia drug fails trials
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets
Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
AbbVie's closely watched schizophrenia drug fails two studies, shares slide
By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug the company acquired last year failed two mid-stage studies, widening rival Bristol Myers Squibb's lead in the market for new treatments for the condition.
AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
Key Takeaways Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.Abbvie said the trials did not show a statistically significant improvement in symptoms compared with the placebo group at week 6.
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays Stoic
Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug trial failed to meet their primary endpoint. AbbVie said its two phase 2 EMPOWER trials investigating emraclidine as a once-daily,
AbbVie shares slip after schizophrenia drug trial misses primary endpoint
Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US trading.
AbbVie Lifts Profit Outlook as Inflammatory Drugs Rinvoq and Skyrizi Beat Estimates
AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, ...
These Stocks Are Moving the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More
Tesla stock extends gains after the electric-vehicle maker’s market cap closes above $1 trillion for the first time since ...
AbbVie: 3 Positives From The Earnings Report
With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...
bovnews7d
The AbbVie Inc Stock Thriller: Decoding the Mystery Behind ABBV’s Recent Movements
On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...
MarketWatch4d
AbbVie Inc. stock outperforms competitors despite losses on the day
AbbVie Inc. closed $6.12 short of its 52-week high ($207.32), which the company achieved on October 31st. Supported by world-class markets data from Dow Jones and FactSet, and partnering with ...
AbbVie’s Strong Market Position and Promising Pipeline Justify Buy Rating
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Yahoo Finance6d
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis delves into the company's financials and strategic ...
Nasdaq12d
AbbVie Boosts FY24 Outlook; Boosts Dividend 5.8% - Update
(RTTNews) - While reporting financial results for the third quarter on Wednesday, biopharmaceutical company AbbVie, Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2024.
Insider Monkey7d
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy Right Now?
AbbVie Inc. (NYSE:ABBV) also raised its full-year revenue forecast by $500 million and adjusted EPS guidance to $10.90-$10.94. Moreover, demand for the company’s Skyrizi and Rinvoq remains high ...
Yahoo Finance6d
Should We Be Delighted With AbbVie Inc.'s (NYSE:ABBV) ROE Of 75%?
To keep the lesson grounded in practicality, we'll use ROE to better understand AbbVie Inc. (NYSE ... it measures the profitability of a company in relation to shareholder's equity.
AbbVie: Strong Growth Momentum and Strategic Shifts Highlight Compelling Investment Opportunity
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Chris Schott ...